Cybin (CYBN) and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s...
- Preliminary data confirm Flow's ability to successfully measure neuro-effect of ketamine over 10 days -
- Results to be presented at PSYCH Symposium taking...
Advances in Psychedelics can Change Investors’ Minds
Original article(s) on EXBulletin and Financial Times
The science behind this subject has become mainstream in recent years. Excellent BBC documentary Psychedelic trial We explored the implications...
Coming This Monday..
Microdose's Wonderland: Miami Conference to be held at the Adrienne Arsht Center for the Performing Arts in Miami, FL on November 7-9, 2021.
Wonderland: Miami
Full...
Silo Pharma (SILO) $2.67 Announces $1 Million Stock Buyback.
Yes it doesn't sound like a lot of money on the surface. But the stock is so grossly undervalued (in our opinion) and there...
Why Isn’t Big Pharma Jumping Into Psychedelics (PsyTech).
Originally in PsyTech Jan 28, 2021.
By Tessa Eskin
Big Pharma is at a crossroads. The industry’s business model relies largely on returning customers for...
That’s it. $225 Million Raised by Atai (ATAI) Gets us Interested in the Psychedelics...
Redefining how the world approaches, prevents, and heals mental health disorders.
LIVE QUOTE
Initially founded as a holding group that later became involved in operations, Atai...
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating...
A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of applying NeuroDirect™ ketamine topical...
Five Myths About Ketamine and Matthew Perry’s Death (Fox News).
Through the first nine months of the year, global Johnson and Johnson's Spravato Ketamine nasal-spray revenues were $483 million, an 88.8% increase over the...
Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?
Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found in Virtually all...
Cybin (CLXPF CYBN) Gets $8.00 Price Target From H.C. Wainwright.
Advancing Multiple Psychedelics in Multiple Indications; Initiating With a Buy and $8 Price Target.
REPORT
LIVE QUOTE
INVESTOR DECK
Latest article
Cabaletta (CABA) Surges 44% on Massive Volume Spike.
Biotech 12 Pack Off to Nice Start..
Cabaletta up 35%, GeoVax up 75%, and Replimune up 62%. All since late April!
Biotech Stock Review is...
GeoVax (GOVX) Surges 51% on Massive Volume Spike.
MonkeyPox and Gedeptin Related News Spark New Investor Interest.
MARKET BRIEF
On a quiet Wednesday afternoon, the 29th, while we were nearing completion of an updated...
Paving Past Obstacles on the Path to US Biosecurity
GeoVax’s CEO calls on government support to bolster domestic biotechnology and keep pace with China.
National biosecurity has become a frequent topic of conversation in...
